Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines

Journal of Hematology & Oncology

Varsha Gandhi⁵  Christine Marie Stellrecht⁵  Michael Wang²  Sanjeev Redkar³  Pietro Taverna³  Veera Baladandayuthapani⁵  Jiexin Zhang¹  Kumudha Balakrishnan⁵  Shujun Shentu⁴  Shadia Zaman⁴  Cornel Joseph Phillip⁵ 

[1] Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Astex Pharmaceuticals, Inc., Dublin, California, USA;Departments of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA;Graduate School of Biomedical Sciences, The University of Texas Health Science Center, Houston, Texas, USA

关键词: Multiple myeloma;    MP470;    amuvatinib;    HGF;    MET;   

Others  :  802351
DOI  :  10.1186/1756-8722-6-92

 received in 2013-11-03, accepted in 2013-12-02,  发布年份 2013

【 摘 要 】

Background

MET is a receptor tyrosine kinase that is activated by the ligand HGF and this pathway promotes cell survival, migration, and motility. In accordance with its oncogenic role, MET is constitutively active, mutated, or over-expressed in many cancers. Corollary to its impact, inhibition of MET kinase activity causes reduction of the downstream signaling and demise of cells. In myeloma, a B-cell plasma malignancy, MET is neither mutated nor over-expressed, however, HGF is increased in plasma or serum obtained from myeloma patients and this was associated with poor prognosis. The small-molecule, amuvatinib, inhibits MET receptor tyrosine kinase. Based on this background, we hypothesized that targeting the HGF/MET signaling pathway is a rational approach to myeloma therapy and that myeloma cells would be sensitive to amuvatinib.

Methods

Expression of MET and HGF mRNAs in normal versus malignant plasma cells was compared during disease progression. Cell death and growth as well as MET signaling pathway were assessed in amuvatinib treated primary myeloma cells and cell lines.

Results

There was a progressive increase in the transcript levels of HGF (but not MET) from normal plasma cells to refractory malignant plasma cells. Amuvatinib readily inhibited MET phosphorylation in primary CD138+ cells from myeloma patients and in concordance, increased cell death. A 48-hr amuvatinib treatment in high HGF-expressing myeloma cell line, U266, resulted in growth inhibition. Levels of cytotoxicity were time-dependent; at 24, 48, and 72 h, amuvatinib (25 μM) resulted in 28%, 40%, and 55% cell death. Consistent with these data, there was an amuvatinib-mediated decrease in MET phosphorylation in the cell line. Amuvatinib at concentrations of 5, 10, or 25 μM readily inhibited HGF-dependent MET, AKT, ERK and GSK-3-beta phosphorylation. MET-mediated effects were not observed in myeloma cell line that has low MET and/or HGF expression.

Conclusions

These data suggest that at the cellular level MET/HGF pathway inclines with myeloma disease progression. Amuvatinib, a small molecule MET kinase inhibitor, is effective in inducing growth inhibition and cell death in myeloma cell lines as well as primary malignant plasma cells. These cytostatic and cytotoxic effects were associated with an impact on MET/HGF pathway.

【 授权许可】

   
2013 Phillip et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998, 91:3-21.
• [2]Piazza FA, Gurrieri C, Trentin L, Semenzato G: Towards a new age in the treatment of multiple myeloma. Ann Hematol 2007, 86:159-172.
• [3]Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K: Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012, 9:135-143.
• [4]Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet 2009, 374:324-339.
• [5]Roodman GD: Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010, 28:244-250.
• [6]Podar K, Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
• [7]Derksen PW, De Gorter DJ, Meijer HP, Bende RJ, Van Dijk M, Lokhorst HM, Bloem AC, Spaargaren M, Pals ST: The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003, 17:764-774.
• [8]Yasui H, Hideshima T, Richardson PG, Anderson KC: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol 2006, 132:385-397.
• [9]Hideshima T, Podar K, Chauhan D, Anderson KC: Cytokines and signal transduction. Best Pract Res Clin Haematol 2005, 18:509-524.
• [10]Song L, Li Y, Sun YX, Yu M, Shen BF: IL-6 inhibits apoptosis of human myeloma cell line XG-7 through activation of JAK/STAT pathway and up-regulation of Mcl-1. Ai Zheng 2002, 21:113-116.
• [11]Stellrecht CM, Gandhi V: MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett 2009, 280:1-14.
• [12]Naldini L, Vigna E, Ferracini R, Longati P, Gandino L, Prat M, Comoglio PM: The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991, 11:1793-1803.
• [13]Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991, 6:501-504.
• [14]Rodrigues GA, Park M: Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene 1994, 9:2019-2027.
• [15]Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST: Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 2002, 99:1405-1410.
• [16]Tjin EPM, Groen RWJ, Vogelzang I, Derksen PWB, Klok MD, Meijer HP, van Eeden S, Pals ST, Spaargaren M: Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006, 107:760-768.
• [17]Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
• [18]Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996, 88:3998-4004.
• [19]Borset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A: Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996, 271:24655-24661.
• [20]Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The nordic myeloma study group. Blood 1998, 91:806-812.
• [21]Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, Sanderson RD, Waage A, Sundan A: High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood 2000, 96:3139-3146.
• [22]Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kitano M, Kakishita E: Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma. Br J Haematol 2002, 116:796-802.
• [23]Seidel C, Lenhoff S, Brabrand S, Anderson G, Standal T, Lanng-Nielsen J, Turesson I, Borset M, Waage A: Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy. Br J Haematol 2002, 119:672-676.
• [24]Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS: Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol 2003, 72:229-233.
• [25]Kara IO, Sahin B, Gunesacar R, Unsal C: Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma. Adv Ther 2006, 23:635-645.
• [26]Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K, Possinger K: Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. Eur J Haematol 2001, 66:83-88.
• [27]Pour L, Svachova H, Adam Z, Mikulkova Z, Buresova L, Kovarova L, Buchler T, Penka M, Vorlicek J, Hajek R: Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma. Neoplasma 2010, 57:29-34.
• [28]Ludek P, Hana S, Zdenek A, Martina A, Dana K, Tomas B, Lucie K, Marta K, Jaroslav M, Miroslav P, et al.: Treatment response to bortezomib in multiple myeloma correlates with plasma hepatocyte growth factor concentration and bone marrow thrombospondin concentration. Eur J Haematol 2010, 84:332-336.
• [29]Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J, Hajek R: Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response. Ann Hematol 2010, 89:385-389.
• [30]Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, Sundan A: Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999, 94:3883-3888.
• [31]Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A: HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007, 109:3024-3030.
• [32]Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V: Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res 2007, 67:9913-9920.
• [33]Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V: Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol 2009, 63:587-597.
• [34]Chen LS, Stellrecht CM, Gandhi V: RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol 2008, 140:682-691.
• [35]Mahtouk K, Tjin EP, Spaargaren M, Pals ST: The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 1806, 2010:208-219.
• [36]Qi W, Cooke L, Calaluce R, Bearss D, Mahadevan D: Dual inhibition of receptor tyrosine kinases of PDGFR and EGFR abolishes prostate cancer cell growth in a mouse xenograft model by complete dephosphorylation of PKB/Akt. Proc Am Assoc Cancer Res 2007, 48:5421.
• [37]Tibes R, Berk GI, Fine GD, Choy GS, Tolcher AW: A phase-1 study of MP-470, a novel orally bioavailable small molecule with Rad51 suppression activity. Proc Am Assoc Cancer Res 2008, 49:4083.
• [38]Tolcher AW, Berk GI, Fine GD, Choy GD, Bearss DJ, Redkar S, Tibes R: MP470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study. Proc Am Assoc Cancer Res 2008, 49:4083.
• [39]Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B: Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010, 10:198. BioMed Central Full Text
• [40]Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, et al.: Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007, 67:2982-2989.
• [41]Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al.: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
• [42]Meads MB, Hazlehurst LA, Dalton WS: The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008, 14:2519-2526.
• [43]Zhang W, Huang P: Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity. Cancer Biol Ther 2011, 11:150-156.
• [44]Druker BJ: Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004, 91:1-30.
• [45]Rodrigues GA, Naujokas MA, Park M: Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing. Mol Cell Biol 1991, 11:2962-2970.
• [46]Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M: A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res 2004, 10:6686-6694.
• [47]Tolcher AW, Mita M, Gordon M, Rosen L, Patnaik A, Mita A, Fine GD, Choy GS, Berk GI: Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-Ib clinical trial. Proc Am Assoc Cancer Res 2008, 49:403.
• [48]Mahadevan D, Cooke L, Riley C, Swart R, Simons B, Della Croce K, Wisner L, Iorio M, Shakalya K, Garewal H, et al.: A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors. Oncogene 2007, 26:3909-3919.
• [49]Trevor K, Combs D, Mahadevan D, Bearss D, Cranmer L: Activity of the multi-targeted, receptor tyrosine kinase inhibitor MP470 against synovial sarcoma cells. Proc Am Assoc Cancer Res 2008, 49:4891.
• [50]Welsh JW, Mahadevan D, Ellsworth R, Cooke L, Bearss D, Stea B: The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol 2009, 4:69. BioMed Central Full Text
• [51]Tibes R, Fine G, Choy G, Redkar S, Taverna P, Oganesian A, Sahai A, Azab M, Tolcher AW: A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2013, 71:463-471.
• [52]Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ: ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010, 9:1544-1553.
• [53]Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC: Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem 2011, 286:20666-20676.
• [54]Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, et al.: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011, 29:3307-3315.
• [55]Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, et al.: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011, 29:1271-1279.
• [56]Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS: Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012, 118:5903-5911.
• [57]Previdi S, Abbadessa G, Dalo F, France DS, Broggini M: Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther 2012, 11:214-223.
• [58]Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, et al.: Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012, 118:5894-5902.
• [59]Zaman S, Stellrecht CM, Shentu S, Orlowski R, Gandhi V: Targeting the pro-survival protein c-MET with ARQ 197 inhibits growth of multiple myeloma cells. Proc Am Assoc Cancer Res 2012, 53:844.
• [60]Dorkhom SJ, Zaman S, Thomas SK, Alexanian R, Shah JJ, Weber DM, Wang M, Anderson ML, Baladandayuthapani V, Lin YH, et al.: Phase II study of the c-Met inhibitor ARQ 197 (tivantinib) in patients with relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2012, 120:2976.
• [61]Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, et al.: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
• [62]Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM: Development and characterization of a Melphalan-resistant human multiple myeloma cell line. Cancer Res 1991, 51:995-1002.
• [63]Manshouri T, Estrov Z, Quintas-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S: Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011, 71:3831-3840.
• [64]Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST: 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 2001, 61:5474-5479.
• [65]Bjorklund CC, Ma W, Wang ZQ, Davis RE, Kuhn DJ, Kornblau SM, Wang ML, Shah JJ, Orlowski RZ: Evidence of a role for activation of Wnt/b-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011, 286:11009-11020.
• [66]Stellrecht CM, Ayres M, Arya R, Gandhi V: A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat 2010, 121:355-364.